TKI-话题@MedSci

#TKI#

128篇内容 | 5087人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1384208, encodeId=5a861384208f5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168217, objectId=b3e216821e12, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b3e216821e12, replyNumber=0, likeNumber=112, createdTime=2019-06-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b3e216821e12, moduleTitle=吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b3e216821e12)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384207, encodeId=b72d138420ee1, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, objectType=article, longId=168149, objectId=6885168149ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6885168149ba, replyNumber=0, likeNumber=91, createdTime=2019-06-13, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6885168149ba, moduleTitle=安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6885168149ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384206, encodeId=08a11384206ce, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, objectType=article, longId=168100, objectId=14f816810048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=14f816810048, replyNumber=0, likeNumber=93, createdTime=2019-06-12, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=14f816810048, moduleTitle=从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=14f816810048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384205, encodeId=92c013842055d, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, objectType=article, longId=167952, objectId=6ae716e9520e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ae716e9520e, replyNumber=0, likeNumber=76, createdTime=2019-06-11, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ae716e9520e, moduleTitle=研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ae716e9520e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384204, encodeId=1903138420463, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, objectType=article, longId=167660, objectId=579916e66023, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=579916e66023, replyNumber=0, likeNumber=0, createdTime=2019-06-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=579916e66023, moduleTitle=ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=579916e66023)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384203, encodeId=8a45138420366, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗, objectType=article, longId=166834, objectId=72d01668345b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=72d01668345b, replyNumber=0, likeNumber=45, createdTime=2019-05-27, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=72d01668345b, moduleTitle=从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=72d01668345b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384202, encodeId=09ef13842021f, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Blood：血栓性微血管病变是三代TKI 帕纳替尼诱发的心血管毒性的潜在机制, objectType=article, longId=163453, objectId=730b163453fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=730b163453fc, replyNumber=0, likeNumber=88, createdTime=2019-04-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=730b163453fc, moduleTitle=Blood：血栓性微血管病变是三代TKI 帕纳替尼诱发的心血管毒性的潜在机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=730b163453fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384201, encodeId=76241384201f8, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, objectType=article, longId=163018, objectId=a01b163018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a01b163018c7, replyNumber=0, likeNumber=85, createdTime=2019-03-28, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a01b163018c7, moduleTitle=徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a01b163018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384200, encodeId=cca51384200c7, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=EGFR-TKI不良反应管理专家共识, objectType=article, longId=162988, objectId=b029162988bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b029162988bd, replyNumber=0, likeNumber=45, createdTime=2019-03-27, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b029162988bd, moduleTitle=EGFR-TKI不良反应管理专家共识, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b029162988bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384199, encodeId=7d8d138419979, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, objectType=article, longId=160819, objectId=e400160819af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e400160819af, replyNumber=0, likeNumber=74, createdTime=2019-02-24, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e400160819af, moduleTitle=Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e400160819af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384198, encodeId=f89a1384198d5, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, objectType=article, longId=159801, objectId=957315980197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=957315980197, replyNumber=0, likeNumber=145, createdTime=2019-02-13, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=957315980197, moduleTitle=Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=957315980197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384197, encodeId=fdc9138419e73, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素, objectType=article, longId=159074, objectId=2e171590e4ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2e171590e4ea, replyNumber=0, likeNumber=70, createdTime=2019-01-29, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2e171590e4ea, moduleTitle=JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2e171590e4ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384196, encodeId=37d6138419646, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, objectType=article, longId=157519, objectId=39d615e51935, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=39d615e51935, replyNumber=0, likeNumber=49, createdTime=2019-01-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=39d615e51935, moduleTitle=专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=39d615e51935)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384195, encodeId=c955138419502, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, objectType=article, longId=156473, objectId=032c1564e304, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=032c1564e304, replyNumber=0, likeNumber=89, createdTime=2018-12-25, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=032c1564e304, moduleTitle=CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=032c1564e304)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384194, encodeId=8dbf138419455, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, objectType=article, longId=155981, objectId=0cdf1559810c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0cdf1559810c, replyNumber=0, likeNumber=87, createdTime=2018-12-19, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0cdf1559810c, moduleTitle=韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0cdf1559810c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384193, encodeId=7f0a1384193ba, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, objectType=article, longId=155682, objectId=41eb155682eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41eb155682eb, replyNumber=0, likeNumber=130, createdTime=2018-12-14, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41eb155682eb, moduleTitle=何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41eb155682eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384192, encodeId=ba5d1384192dc, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, objectType=article, longId=154710, objectId=3672154e10c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3672154e10c1, replyNumber=0, likeNumber=49, createdTime=2018-12-01, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3672154e10c1, moduleTitle=【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3672154e10c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384191, encodeId=680013841913c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, objectType=article, longId=150184, objectId=a0d515018464, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a0d515018464, replyNumber=0, likeNumber=98, createdTime=2018-10-02, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a0d515018464, moduleTitle=【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a0d515018464)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384190, encodeId=d6471384190b9, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, objectType=article, longId=147673, objectId=4a4a14e6733c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a4a14e6733c, replyNumber=0, likeNumber=94, createdTime=2018-08-31, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a4a14e6733c, moduleTitle=JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4a14e6733c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384189, encodeId=b2101384189f2, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, objectType=article, longId=144828, objectId=bdde144828d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdde144828d7, replyNumber=0, likeNumber=67, createdTime=2018-07-22, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdde144828d7, moduleTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdde144828d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

吴一龙教授：从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

安全性和有效性双管齐下 ——关注EGFR-TKI肝毒性聚焦药物相互作用

2019-06-13

lsj628 (审核中...)

前往app查看评论内容

#TKI#

从奥希替尼联合抗血管生成看EGFR-TKI耐药问题的解决

2019-06-12

lsj628 (审核中...)

前往app查看评论内容

#TKI#

研究分析:血浆EGFR突变早期清除预测EGFR-TKI疗效

2019-06-11

lsj628 (审核中...)

前往app查看评论内容

#TKI#

ASCO2019 |化疗优于EGFR TKI？中国晚期NSCLC EGFR 20外显子插入突变患者的真实世界治疗结果

2019-06-06

lsj628 (审核中...)

前往app查看评论内容

#TKI#

从循证医学证据谈EGFR-TKI辅助治疗适宜人群及术后寡转移的治疗

2019-05-27

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Blood：血栓性微血管病变是三代TKI 帕纳替尼诱发的心血管毒性的潜在机制

2019-04-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

徐松涛教授：EGFR-TKI在EGFR敏感突变非小细胞肺癌全程管理中的重要地位

2019-03-28

lsj628 (审核中...)

前往app查看评论内容

#TKI#

EGFR-TKI不良反应管理专家共识

2019-03-27

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Radiology：耐受EGFR-TKI治疗的非小细胞肺癌的CT征象

2019-02-24

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Lung Cancer：亚洲人群分析！PD-L1高表达提示EGFR突变肺腺癌对EGFR-TKI的原发耐药！

2019-02-13

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO：MET扩增是EGFR受体突变非小细胞肺癌患者TKI耐药的关键因素

2019-01-29

lsj628 (审核中...)

前往app查看评论内容

#TKI#

专家“亿”周谈——聚焦套细胞淋巴瘤新进展，BTKi 伊布替尼有望树立治疗新规则

2019-01-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

CLIN CANCER RES：MERTK抑制剂联合EGFR TKI治疗非小细胞肺癌

2018-12-25

lsj628 (审核中...)

前往app查看评论内容

#TKI#

韩宝惠教授：三代EGFR TKI奥希替尼防控肺癌脑转移效果显著

2018-12-19

lsj628 (审核中...)

前往app查看评论内容

#TKI#

何勇教授：第三代EGFR TKI奥希替尼的一线使用经验探讨

2018-12-14

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【2018 ASH】张薇教授盘点BTKi伊布替尼联合治疗亮点

2018-12-01

lsj628 (审核中...)

前往app查看评论内容

#TKI#

【2018WCLC】逆转耐药，EGFR TKIs耐药后联用阿帕替尼的临床价值再探索

2018-10-02

lsj628 (审核中...)

前往app查看评论内容

#TKI#

JCO：晚期非小细胞肺癌患者Osimertinib或EGFR-TKI治疗的中枢神经系统反应

2018-08-31

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究

2018-07-22

科室
- - 订阅+
  - 更多科室
工具
服务